12:00 AM
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Odanacatib regulatory update

Merck disclosed in its 4Q12 and 2012 earnings that it will delay to 2014 from 1H13 the expected submission of regulatory applications in the U.S., EU and Japan for odanacatib to treat osteoporosis. The pharma said the delay is a result of its decision to include in the submissions data from more than 8,000...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >